Allergan CEO expects drug industry to face pricing heat from Trump

Dec 1 (Reuters) - U.S. President-elect Donald Trump could be more critical of drugmakers and their price increases than the industry expects, Allergan Inc Chief Executive Brent Saunders said on Thursday.

Saunders, speaking at the annual Forbes Healthcare Summit in New York, predicted Trump could be a “more vicious tweeter” against the drug industry than his former Democratic rival Hillary Clinton had been during the campaign.